Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06655818
Status:
TERMINATED
Last Update Posted:
None
First Post:
2024-10-22
Brief Title:
Sub-study of Belantamab Mafodotin GSK2857916 as Monotherapy and in Combination With Dostarlimab GSK4057190 in Participants With RRMM
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase III Randomized Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin GSK2857916 as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With RelapsedRefractory Multiple Myeloma RRMM-DREAMM5 Sub-study 4 - Belantamab Mafodotin and Dostarlimab GSK4057190 in Combination
Status:
TERMINATED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated due to lack of efficacy
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments in each sub-study and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase This study is a sub study of the Master protocol NCT04126200
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None